Friday, November 20, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 66

Galleri wins FDA panel nod as GRAIL chases first multi-cancer screening approval

GRAIL's Galleri blood test just cleared a key FDA advisory vote, putting it on track to become the first FDA-approved multi-cancer screening tool, with a final decision expected in early 2027. The company ran more than 174,000 tests in nine months of 2026 and posted a 24% volume jump in Q3, even as it trades near-term margin for market share.

By the Paparazzi desk November 19, 2026 · 5:53 AM · pluang.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: pluang.com.
  • The source published it on Nov 19, 2026 at 5:53 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

GRAIL's Galleri multi-cancer early detection test cleared a positive vote from an FDA advisory panel, lining it up to become the first multi-cancer screening tool with full FDA approval. A final decision is expected in early 2027. In the meantime, the company says it completed more than 174,000 Galleri tests across the first nine months of 2026, with test volume climbing 24% in the third quarter alone.

GRAIL is chasing reach before profit. It is leaning on promotional pricing to pull in more customers and prioritizing market expansion over short-term margins, with a target of 50-60% gross margins once scale brings costs down. The company is sitting on $788.7 million in cash, which it says will fund both that growth push and its efforts to win insurance coverage through 2029.

Sponsored

Health-sector stocks on Pluang's US list were mixed on Nov 19, 2026, with 69 of 150 names gaining and 76 declining. Among the movers: ALMS sat at USD 4.39, down 9.30%, while BFLY rose 8.87% to USD 6.26 and SYRE climbed 8.30% to USD 101.60. Typical hold times on those names run between 6 and 23 days.

TopicsGRAIL · Galleri · FDA · Pluang · ALMS · BFLY · SYRE

Share

Source: pluang.com

Written by AI from verified reporting.

More stories

  • Health & science 03:46 UTC · 3 hours ago · techtimes.com 2 sources· 2 views
    FDA Clears Regeneron's Quarterly RNA Shot Livsayis for Myasthenia Gravis
  • Health & science 03:27 UTC · 3 hours ago · reuters.com · Caught by @Coen · 2 views
    FDA stands up internal council to vet vaccines and gene therapies after approval
  • Health & science 19:17 UTC · 12 hours ago · medicalxpress.com · Caught by @boxlink · 4 views
    The brain builds a word blueprint a quarter-second before you speak, UCSF finds
  • Health & science 18:54 UTC · 12 hours ago · adelaide.edu.au · Caught by @boxlink · 2 views
    Adelaide quantum team ditches hundreds of loops, keeps sensor sensitivity
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.